FreshLeaf Analytics News

Patient access to medical cannabis October figures released by Rhys Cohen 1. Record growth continues Another record month for medicinal cannabis approvals in Australia via the Special Access Scheme Category B route! 3,594 approvals were issued in October 2019. It’s worth remembering how far the Australian market has come in just the last 12 months....Read More

Australia’s Most Comprehensive Medicinal Cannabis Patient, Product and Pricing Analysis released FreshLeaf Analytics has released Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis. The study was conducted in Q3 2019 and includes insights into the pricing and availability of legal medicinal cannabis products in the Australian marketplace including: Number of products in market...Read More

The last 2 years have seen a huge amount of speculation in Australia around medicinal cannabis stocks. A number of companies have listed on the ASX, raising substantial amounts of capital and seeing their market caps rise to astronomical levels. Auscann, one of the early movers in the medicinal cannabis game that traces its roots...Read More

Australian media has in recent years reported on the high costs of medicinal cannabis (also known as medicinal marijuana), quoting numbers as high as $40K per year for patient treatment. But does it actually cost this much? In most cases the numbers quoted are referencing patients with epilepsy who are taking extremely high dosages. Numerous...Read More

FreshLeaf Analytics, in collaboration with Cannabis Access Clinics has released Australia’s first pricing analysis for legal medicinal cannabis The study was conducted in Q3 2018 and includes insights into the pricing and availability of legal medicinal cannabis products in the Australian marketplace including:  – The number of products available to doctors has increased more than...Read More